Safety of RG2077 in Patients With Multiple Sclerosis
What it found
A paper reports the results; we have not read it yet. See Papers below.
What was tested
Treatment tested
- Abatacept
T-lymphocyte activation antigen CD80 inhibitor|T-lymphocyte activation antigen CD86 inhibitor
What it measured
Main measures
Safety assessment including a MRI, neurological and physical examinations
Throughout study
MRI lesionsSafety
Other measures (1)
Number of gadolinium (GD) enhancing lesions and T2 lesion volume on MRI
Throughout study
MRI lesions
Who could take part
Relapsing MS · 18 to 55
Inclusion Criteria * Confirmed diagnosis of MS, defined as an MRI consistent with MS plus two separate clinical events, or one clinical event and MRI consistent with demyelination plus a second MRI demonstrating new lesions * Have declined all FDA approved therapies for MS
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
Multiple sclerosis (MS) is an autoimmune disorder. In this disease, the body's immune system attacks and destroys the cells that cover and protect nerves. This study will test the safety of a new drug called RG2077 that is designed to treat MS. The study will not determine whether RG2077 is effective in treating MS, only whether it is safe to use in patients with MS. Study hypothesis: RG2077 will arrest MS if administered early in the course of MS and decrease accumulation of lesions on MRI.
Papers
Loading reviews and guidelines…
Related trials
- LTS18002
Phase 3 · Not yet recruiting
Still running
- FREXALT
Phase 3 · Running, not recruiting
Still running
- LITMUS
Not a drug-phase study · Completed (inferred)
Results posted, no main test reported
- Efficacy and Safety Study of Dapirolizumab pegol (BIIB133) in Participants with RMS
Phase 2 · Stopped early
Stopped early
- SUSTAIN
Phase 3 · Stopped early
Stopped early
- ZEUS
Not a drug-phase study · Stopped
Stopped early
History
Started
Jan 2003
Finished
Feb 2006
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error